国内外糖尿病临床研究注册和用药情况及中国现状分析

Registration of Diabetes Related Clinical Research at Home and Abroad and Analysis of Current Situation in China

检索权威临床研究注册机构和Pub Med数据库,统计分析全球糖尿病临床研究注册和论文发表情况,同时结合中国目前的现状进行分析。结果显示全球糖尿病临床研究占总临床研究的数量仍偏低。中国目前糖尿病的临床研究总体数量偏低,但近十年的临床研究数量呈现逐年上升趋势。糖尿病临床研究用药主要包括传统的胰岛素、二甲双胍,而新型的二肽基肽酶4(DPP-4)抑制药、胰高血糖素样肽-1(GLP-1)类似物、钠-葡萄糖共转运蛋白2(SGLT2)抑制药等的研究成为近年来的热点。总体而言,国内外糖尿病临床研究整体偏薄弱,而糖尿病临床研究注册呈现逐年上升趋势,且向新型降糖药物转变。

The status of global diabetes related clinical research registration and publication was analyzed by searching statistical authority clinical research register and pubmed database, and at the same time, the current situation in China was analyzed. Analysis showed that the number of clinical studies on diabetes in the world was still low while the total number of clinical studies on diabetes in China was also low. However, the data of the past ten years showed that the number of clinical studies on diabetes in China upward trend year by year. Researches mainly included the insulin, metformin, dipeptidyl peptidase 4 inhibitor （DPP4i）, glucagon-like peptide-1 （GLP-1） analogs, sodium-glucose cotransporter 2 inhibitor （ SGLT2i）, in which DPP4i, GLP-1 analogs and SGLT2i had become hot in recent years. Overall, the clinical research on diabetes was weak and the registration of clinical studies of diabetes at home and abroad had been on the rise year by year, and had changed to a new type of hypoglycemic drug.